This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..
Fusion (FUSN) Up 99% on $2.4B Buyout Offer From AstraZeneca
by Zacks Equity Research
AstraZeneca (AZN) is set to acquire Fusion Biopharma (FUSN) for $21 per share in cash, along with a contingent value right of $3 per share, tied to a regulatory milestone.
AstraZeneca (AZN) to Buy Fusion Pharmaceuticals for $2.4B
by Zacks Equity Research
AstraZeneca (AZN) has offered to acquire Fusion for $21.00 per share in cash plus a contingent value (CV) payment of $3.00 per share.
Bristol Myers' (BMY) Abecma Gets ODAC Votes for Label Expansion
by Zacks Equity Research
Bristol Myers' (BMY) Abecma gets eight out of 11 votes from the FDA's ODAC for patients with triple-class exposed relapsed or refractory multiple myeloma in earlier lines of therapy.
Bristol Myers Squibb (BMY) Stock Moves -0.29%: What You Should Know
by Zacks Equity Research
Bristol Myers Squibb (BMY) closed the most recent trading day at $52.34, moving -0.29% from the previous trading session.
Bristol Myers (BMY) Gets FDA Nod for Breyanzi's Label Expansion
by Zacks Equity Research
Bristol Myers (BMY) obtains FDA approval for the label expansion of CAR T cell therapy, Breyanzi, for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Bristol Myers Squibb (BMY) Sees a More Significant Dip Than Broader Market: Some Facts to Know
by Zacks Equity Research
Bristol Myers Squibb (BMY) concluded the recent trading session at $52.49, signifying a -0.3% move from its prior day's close.
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Bristol Myers (BMY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Bristol Myers Squibb (BMY) Stock Dips While Market Gains: Key Facts
by Zacks Equity Research
In the most recent trading session, Bristol Myers Squibb (BMY) closed at $53.28, indicating a -0.19% shift from the previous trading day.
Amgen (AMGN) Down 6.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Gilead (GILD) & MRK's HIV Oral Combo Shows Efficacy in Phase II
by Zacks Equity Research
Gilead (GILD) and Merck's (MRK) phase II study data demonstrates the efficacy of their oral once-weekly combination of islatravir and lenacapavir in maintaining viral suppression in individuals with HIV.
Bristol Myers Squibb (BMY) Rises But Trails Market: What Investors Should Know
by Zacks Equity Research
In the most recent trading session, Bristol Myers Squibb (BMY) closed at $50.89, indicating a +0.28% shift from the previous trading day.
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.
CytomX (CTMX) to Report Q4 Earnings: Here's What to Expect
by Zacks Equity Research
Investor focus is likely to be on CytomX Therapeutics' (CTMX) updates on key cancer immunotherapeutic candidates, CX-904 and BMS-986288, on the fourth-quarter 2023 earnings call.
New Strong Sell Stocks for February 26th
by Zacks Equity Research
BXMT, BMY and CWEN have been added to the Zacks Rank #5 (Strong Sell) List on February 26, 2023.
Karuna's (KRTX) Q4 Loss Widens, Focus on Bristol Myers Buyout
by Zacks Equity Research
Karuna's (KRTX) fourth-quarter 2023 earnings and revenues miss estimates. The company is set to be acquired by Bristol Myers.
Bristol Myers' (BMY) Krazati sNDA for CRC Gets Priority Review
by Zacks Equity Research
Bristol Myers (BMY) announces FDA's acceptance of the sNDA seeking approval for the Krazati/Erbitux combo therapy to treat CRC patients. A final decision is expected on Jun 21, 2024.
Prothena (PRTA) Q4 Earnings Miss Estimates on Higher R&D Expense
by Zacks Equity Research
Prothena (PRTA) posts a wider-than-expected loss in the fourth quarter on lower revenues and higher costs.
Gilead (GILD) to Buy CBAY for $4.3B, Add PBC Drug to Pipeline
by Zacks Equity Research
Gilead (GILD) is all set to acquire CymaBay Therapeutics for $4.3 billion and strengthen its liver disease portfolio with the addition of seladelpar to its pipeline.
A Look at Pharma ETFs After Q4 Earnings
by Sweta Killa
The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth. However, many industry bigwigs reported solid results, with some beating on earnings or revenues or both.
New Strong Sell Stocks for February 12th
by Zacks Equity Research
ACLS, BMY and CHX have been added to the Zacks Rank #5 (Strong Sell) List on February 12, 2023.
The Zacks Analyst Blog Highlights Gilead Sciences, Bristol Myers, Amgen, Morphysys and REGENXBIO
by Zacks Equity Research
Gilead Sciences, Bristol Myers, Amgen, Morphysys and REGENXBIO are included in this Analyst Blog.
Biotech Stock Roundup: GILD, AMGN & BMY's Q4 Results, MOR Up on NVS Deal & More
by Zacks Equity Research
Earnings of Gilead (GILD) and Amgen (AMGN) are in focus in the biotech sector.
Bristol Myers' (BMY) Opdivo Label Expansion Filings Get Accepted
by Zacks Equity Research
Bristol Myers (BMY) announces the acceptance of its regulatory filings for the perioperative Opdivo regimen to treat a lung cancer indication in the United States and EU.
JAZZ Boosts Oncology Pipeline With KRAS Inhibitor Program
by Zacks Equity Research
JAZZ inks a deal to acquire global rights to Redx Pharma's KRAS inhibitor program to strengthen its early-stage oncology pipeline.
Bristol Myers (BMY), TSVT CAR T-Cell Therapy to Face FDA's ODAC
by Zacks Equity Research
Bristol Myers (BMY) and its partner TSVT announce that the FDA's ODAC will meet in March to review data supporting the label expansion for CAR T-cell therapy.